NASDAQ:NVLN - Novelion Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.16 -0.12 (-9.38 %)
(As of 12/10/2018 08:19 AM ET)
Previous Close$1.28
Today's Range$1.10 - $1.27
52-Week Range$0.70 - $5.87
Volume563,369 shs
Average Volume1.95 million shs
Market Capitalization$21.96 million
P/E Ratio-0.17
Dividend YieldN/A
Beta1.86
Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVLN
Previous Symbol
CUSIPN/A
Phone617-500-7867

Debt

Debt-to-Equity RatioN/A
Current Ratio0.22
Quick Ratio0.17

Price-To-Earnings

Trailing P/E Ratio-0.17
Forward P/E Ratio-0.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$138.44 million
Price / Sales0.16
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.80 per share
Price / Book1.45

Profitability

EPS (Most Recent Fiscal Year)($6.81)
Net Income$-126,710,000.00
Net Margins-88.21%
Return on Equity-240.54%
Return on Assets-27.06%

Miscellaneous

Employees180
Outstanding Shares18,930,000
Market Cap$21.96 million
OptionableOptionable

Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN."

How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc (NASDAQ:NVLN) issued its earnings results on Friday, November, 9th. The biotechnology company reported ($1.32) EPS for the quarter. The biotechnology company had revenue of $30.33 million for the quarter, compared to the consensus estimate of $34.20 million. Novelion Therapeutics had a negative return on equity of 240.54% and a negative net margin of 88.21%. View Novelion Therapeutics' Earnings History.

When is Novelion Therapeutics' next earnings date?

Novelion Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Novelion Therapeutics.

What price target have analysts set for NVLN?

2 brokerages have issued 12-month target prices for Novelion Therapeutics' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Novelion Therapeutics' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 331.0% from the stock's current price. View Analyst Price Targets for Novelion Therapeutics.

What is the consensus analysts' recommendation for Novelion Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novelion Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novelion Therapeutics.

Has Novelion Therapeutics been receiving favorable news coverage?

News articles about NVLN stock have trended very positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Novelion Therapeutics earned a news impact score of 3.9 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.

Who are some of Novelion Therapeutics' key competitors?

Who are Novelion Therapeutics' key executives?

Novelion Therapeutics' management team includes the folowing people:
  • Dr. Mark H. N. Corrigan, Exec. Chairman (Age 60)
  • Mr. Benjamin S. Harshbarger, Interim CEO, Gen. Counsel & Corp. Sec. (Age 49)
  • Mr. Michael D. Price, Exec. VP & CFO (Age 60)
  • Mr. Roger W. Louis, Global Chief Compliance Officer & Sr. VP (Age 62)
  • Ms. Barbara Y. Chan, VP & Chief Accounting Officer (Age 54)

Who are Novelion Therapeutics' major shareholders?

Novelion Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (9.13%), Prosight Management LP (2.36%) and Context Partners Fund L.P. (0.34%). Company insiders that own Novelion Therapeutics stock include Donald K Stern and Jason Aryeh. View Institutional Ownership Trends for Novelion Therapeutics.

Which institutional investors are selling Novelion Therapeutics stock?

NVLN stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC. View Insider Buying and Selling for Novelion Therapeutics.

Which institutional investors are buying Novelion Therapeutics stock?

NVLN stock was bought by a variety of institutional investors in the last quarter, including Prosight Management LP and Context Partners Fund L.P.. Company insiders that have bought Novelion Therapeutics stock in the last two years include Donald K Stern and Jason Aryeh. View Insider Buying and Selling for Novelion Therapeutics.

How do I buy shares of Novelion Therapeutics?

Shares of NVLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of NVLN stock can currently be purchased for approximately $1.16.

How big of a company is Novelion Therapeutics?

Novelion Therapeutics has a market capitalization of $21.96 million and generates $138.44 million in revenue each year. The biotechnology company earns $-126,710,000.00 in net income (profit) each year or ($6.81) on an earnings per share basis. Novelion Therapeutics employs 180 workers across the globe.

What is Novelion Therapeutics' official website?

The official website for Novelion Therapeutics is http://www.novelion.com.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company can be reached via phone at 617-500-7867 or via email at [email protected]


MarketBeat Community Rating for Novelion Therapeutics (NASDAQ NVLN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  316
MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe NVLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by MarketBeat.com Staff

Featured Article: Trading Penny Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel